文献速递精神分裂症与精神病性障碍

精神分裂症症状域改善的时间进程:六项抗精神病药试验的个体参与者数据分析

Temporal course of symptom domain improvement in schizophrenia: individual participant data analysis of six antipsychotic drug trials.
PubMed 文献 · Lancet Psychiatry · 2026-01-01

该研究分析六项抗精神病药试验的2079例急性精神分裂症患者个体数据,发现五个PANSS症状域在治疗前几周均显著改善,约15周后趋于平台。敌意/兴奋应答中位时间3周,阳性症状和焦虑/抑郁4周,阴性症状及认知/紊乱症状8周。

要点

  • 敌意/兴奋症状改善最快,阳性症状次之,阴性及认知/紊乱症状改善最慢。
  • 阴性症状和认知/紊乱症状持续存在时不应过早调整治疗。
  • 各症状域改善在前几周显著,约15周后缓慢进入平台期。

核心结论

  • 抗精神病药治疗中敌意/兴奋症状最先达到实质应答,其次为阳性症状,阴性和认知/紊乱症状改善明显滞后。
  • 临床不应在阴性症状和认知/紊乱症状持续时过早更改治疗。

研究设计与样本

  • 对现有数据库中六项为期6-12个月的急性精神分裂症抗精神病药试验进行个体参与者数据分析,共2079例患者。
  • 采用描述性统计、应答时间分析和路径分析,应答阈值定义为各症状域至少50%症状减轻。

主要发现

  • 校正基线症状严重度、年龄和性别后,敌意/兴奋应答中位时间3周(95%CI 3至3)。
  • 阳性症状和焦虑/抑郁应答中位时间均为4周,阴性症状和认知/紊乱症状均为8周(95%CI 6至9)。

关键数值与推荐

  • 应答定义为各PANSS症状域至少50%症状减轻。
  • 敌意/兴奋应答中位时间3周(95%CI 3至3),阳性症状4周(95%CI 4至4),焦虑/抑郁4周(95%CI 4至4)。
  • 阴性症状应答中位时间8周(95%CI 6至9),认知/紊乱症状8周(95%CI 6至9)。

临床怎么用

  • 临床应预期敌意/兴奋和阳性症状较早出现实质应答,阴性和认知/紊乱症状改善较慢。
  • 当阴性症状和认知/紊乱症状持续时,避免过早更改治疗方案。

局限性

  • 探索性路径分析仅提示阴性症状改善中很小比例由认知/紊乱和焦虑/抑郁域改善介导。
  • 研究未纳入有生活经验者参与项目。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The temporal course of antipsychotic drug action in schizophrenia remains poorly understood. We aimed to explore how different symptom domains of schizophrenia improve over time. Such knowledge has important implications for treatment decisions and for understanding the mechanisms of action of antipsychotic drugs. METHODS: We analysed individual patient data from an existing repository comprising six antipsychotic drug trials of 6-12 months' duration in patients with acute schizophrenia (n=2079; 1328 [64%] men, 751 [36%] women; 1577 [76%] White, 502 [24%] non-White; mean age 34·72 years [range 16-73]). We used descriptive statistics to examine improvement trajectories across five PANSS symptom domains according to an established five-factor model (positive symptoms, negative symptoms, hostility and excitement, anxiety and depression, and cognitive and disorganisation). Time-to-response analyses were conducted using a threshold of at least 50% symptom reduction to define response within each domain. We used path analysis to explore whether improvements in negative, positive, and cognitive symptoms were mediated by changes in other symptom domains. People with lived experience were not involved in the project. FINDINGS: All five symptom domains showed substantial improvements during the first weeks of treatment, which slowly plateaued from week 15 onwards. While the factors improved in parallel, some improved more than others. Within the first 6 months, on average, hostility and excitability symptoms decreased by 76% (95% CI -80·5 to -71·1) from baseline, positive symptoms by 64% (-68·0 to -60·5), anxiety and depression symptoms by 57% (-61·2 to -53·2), cognitive and disorganisation symptoms by 61% (-64·0 to -57·2), and negative symptoms by 50% (-53·9 to -46·4). Median time to response adjusted for baseline symptom severity, age, and sex, was 3 weeks (95% CI 3 to 3, restricted mean survival time [RMST] 6·60, SE 0·20)) for hostility and excitement and 4 weeks for positive symptoms (4 to 4, RMST 7·76, SE 0·20) and anxiety and depression symptoms (4 to 4, RMST 8·71, SE 0·22), compared with 8 weeks for negative symptoms (6 to 9, RMST 12·45, SE 0·25) and cognitive and disorganisation symptoms (6 to 9, RMST 12·06, SE 0·25). Exploratory investigations using path analysis suggested that only a small proportion of the improvement in negative symptoms was mediated by improvements in cognitive and disorganisation and anxiety and depression domains. INTERPRETATION: Clinicians should be aware of earlier attainment of substantial response of hostility and excitement, then positive symptoms, before substantial reductions in other domains. Treatment changes should not be made prematurely when negative and cognitive and disorganisation symptoms persist, as improvement in these domains lags behind. Researchers should consider these temporal patterns when investigating the mechanisms of action of antipsychotic drugs. FUNDING: None.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Leucht S, Harrer M, Illing S, et al. Temporal course of symptom domain improvement in schizophrenia: individual participant data analysis of six antipsychotic drug trials. Lancet Psychiatry. 2026. PMID: 42456706. doi:10.1016/S2215-0366(26)00174-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。